Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pear Therapeutics Inc (PEAR)

Pear Therapeutics Inc (PEAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,168
  • Shares Outstanding, K 142,739
  • Annual Sales, $ 12,690 K
  • Annual Income, $ -75,490 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.45
  • Price/Sales 0.54
  • Price/Cash Flow N/A
  • Price/Book 0.13
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.70
  • Most Recent Earnings $-0.22 on 11/14/22
  • Next Earnings Date 05/15/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0288 +1.39%
on 04/18/23
0.4800 -93.92%
on 03/21/23
-0.3609 (-92.51%)
since 03/17/23
3-Month
0.0288 +1.39%
on 04/18/23
1.2700 -97.70%
on 02/07/23
-1.1108 (-97.44%)
since 01/18/23
52-Week
0.0288 +1.39%
on 04/18/23
6.7400 -99.57%
on 05/05/22
-4.3108 (-99.33%)
since 04/18/22

Most Recent Stories

More News
Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics Announces Process Exploring Strategic Alternatives

Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate...

PEAR : 0.0292 (-38.91%)
California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program

The California Department of Health Care Services (DHCS) has selected Pear Therapeutics, Inc . (Nasdaq: PEAR), a leader in developing and commercializing software-based medicines, to support the implementation...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement...

PEAR : 0.0292 (-38.91%)
Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the expansion of its collaboration...

PEAR : 0.0292 (-38.91%)

Business Summary

Pear Therapeutics Inc. is involved in developing and commercializing software-based medicines, called prescription digital therapeutics. The company's principal pipeline of products include reset(R), for the treatment of substance use disorder, reSET-O(R), for the treatment of opioid use disorder and...

See More

Key Turning Points

3rd Resistance Point 0.0511
2nd Resistance Point 0.0465
1st Resistance Point 0.0379
Last Price 0.0292
1st Support Level 0.0247
2nd Support Level 0.0201
3rd Support Level 0.0115

See More

52-Week High 6.7400
Fibonacci 61.8% 4.1763
Fibonacci 50% 3.3844
Fibonacci 38.2% 2.5925
Last Price 0.0292
52-Week Low 0.0288

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar